# Andy McGibbon

> Andy McGibbon is a Series A investor at Sonder Capital backing Health Care and Medical Device. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sonder Capital](https://shizune.co/investors/profile/sonder-capital)
- Location: San Francisco, United States
- Total investments: 4
- Last investment: Mar 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/amcgibbon

Andy McGibbon is a Series A investor at Sonder Capital in San Francisco focused on Health Care and Medical Device. Andy McGibbon is the Managing Partner of Sonder Capital. He attended the University of Cincinnati.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 50% |
| Medical Device | 2 | 50% |
| Diabetes | 1 | 25% |
| Biotechnology | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series B | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 1 | 25% |
| The Netherlands | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vitestro | Vitestro transform patient care with autonomous blood drawing technology. | $70M | Series B | Mar 10, 2026 |  |
| Vitestro | Vitestro transform patient care with autonomous blood drawing technology. | $12.9M | Series A | Mar 21, 2023 |  |
| G.I. Windows | G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $16.4M | Series A | Aug 19, 2020 |  |
| G.I. Windows | G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $14.6M | Series A | Dec 11, 2019 |  |

4 of 4 investments shown.

## Co-investors
- [GT Healthcare Capital Partners](https://shizune.co/investors/profile/gt-healthcare-capital-partners) — VC Fund, 2 deals together
- [Addington Investment Group](https://shizune.co/investors/profile/addington-investment-group) — VC Fund, 1 deal together
- [InterVest Co.](https://shizune.co/investors/profile/intervest-co) — VC Fund, 1 deal together
- [JC Investco](https://shizune.co/investors/profile/jc-investco) — VC Fund, 1 deal together
- [Johnson & Johnson Innovation](https://shizune.co/investors/profile/johnson-johnson-innovation-jjdc) — VC Fund, 1 deal together
- [LabCorp Venture Fund](https://shizune.co/investors/profile/labcorp-venture-fund) — VC Fund, 1 deal together

## About Sonder Capital

VC Fund · Redwood City, United States

Sonder Capital invests in teams and technologies that can transform healthcare in the medical device, diagnostic and healthtech sectors. We are Foundational Investors – we commit our energy and capital early to guide and support companies from inception to acquisition or IPO. We look for big ideas that will change lives.

5 contacts available at Sonder Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Andy McGibbon | Managing Partner | https://shizune.co/investors/profile/andy-mcgibbon |
| Colby Wood | Managing Partner | https://shizune.co/investors/profile/colby-wood |
| Jay Watkins | Managing Partner | https://shizune.co/investors/profile/jay-watkins |
| Fred Moll, M.D | Managing Partner | https://shizune.co/investors/profile/fred-mole |
| Kate Garrett | Managing Partner | https://shizune.co/investors/profile/kate-garrett |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Andy McGibbon invest in?

Andy McGibbon invests primarily in Health Care, Medical Device and Diabetes startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Andy McGibbon last invest?

The most recent investment recorded for Andy McGibbon closed in Mar 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co